NAVIGATIONINFORMATION REQUEST |
Richard M. Evans, M.D.
EDUCATIONAL BACKGROUND
Undergraduate Education . Schools: El Camino College (California) and University of Texas at El Paso . Major: Pre-Med/Biological Sciences . Degree: Bachelor of Arts . Graduation Date: August 31, 1968 . Graduate (Non-Professional) Education: None . Professional Education . School: University of Texas Medical Branch at Galveston . Degree: Medical Degree (M.D.) Graduation Date: June 9, 1971
Post Graduate Education . Internship Hospital: Malcolm Grow USAF Medical Center (Washington, D.C.) Specialty: Rotating Internship Dates: July 1, 1971-June 30, 1972 Residency Hospital: University of Texas Health Science San Antonio Specialty: Ophthalmology Dates: July 1, 1972-June 30, 1975 Fellowship Hospital: Armed Forces Institute of Pathology (Washington, D.C.) Specialty: Ophthalmic Pathology Dates: July 18, 1975-August 16, 1976
PROFESSIONAL ORGANIZATION MEMBERSHIPS
1. American Medical Association 2. American Academy of Ophthalmology 3. Texas Medical Association 4. Texas Ophthalmology Association 5. Bexar County Medical Society 6. San Antonio Society of Ophthalmology 7. Society of Air Force Clinical Surgeons 8. Society of Military Ophthalmologists 9. Association of Ophthalmic Alumni of the AFIP 10. Contact Lens Association of Ophthalmologists 11. Irish-American Ophthalmology Association HONORS AND EXECUTIVE POSITIONS HELD 1. Society of Military Ophthalmologists--Secretary/Treasurer 1978-1980 2. Texas Society for the Prevention of Blindness a. San Antonio Branch--Medical Advisor 1981-1984 b. Texas State Medical Advisory Board--Member 1985-1986 3. San Antonio Society of Ophthalmology a. Secretary/Treasurer 1984-1986 b. Assistant Program Chairman 1985-1986, 1987-1988 c. Program Chairman 1986-1987 4. Southwest Texas Methodist Hospital a. Division of Ophthalmology Chairman 1985-1988 b. Special Surgery Quality Assurance Committee (1) Member 1985-1988 (2) Chairman 1986-1987 c. Institutional Review Board 1985-1986 d. Department of Special Surgery--Chairman 1986-1987 e. Surgical Board 1986-1987 f. Planning Committee 1986-1987 g. Executive Committee 1986-1987 5. Prucare--Utilization Review Committee 1985-1991 6. South Texas Health Plan--Medical Review Board 1986-1987 7. Baptist Eye Bank a. Board Member 1987-1998 b. Tissue Utilization Committee 1993-1998 8. South Texas Physician’s Outreach--Honduras Mission Trip Ophthalmologist 1989-1999 9. Oak Hills/Aguascalientes Rotary Club--Aguascalientes Mission Trip Ophthalmologist 1991-1997 10. South Texas Total Eye Care--Quality Review Committee 1996-1999 11. TRS Care, Quality Review Committee, San Antonio, TX , 2001-present 12. TRS Care, Quality Review Committee, San Antonio, Texas 2001-present 13. WellMed/Physicians Health Choice Credentialing Committee 2004-Present 14. University UMC--Salud y Paz Guatemala Medical Mission Trip 2005-Present 15, Texas Monthly Magazine--Texas Super Doctor 2006 16, Texas Monthly Magazine--Texas Super Doctor 2007
PUBLICATIONS
1. Professional Articles a. Folk Medicine in Mexican-American Sub Culture, McKinley, C. and Evans, R.M., Diseases of the Nervous System, April 1969, pp. 264-266. b. Cephalometric X-ray: An Evaluation of Cleft Palate Patients After Maxillary Bone Grafting, Evans, R.M., Texas Reports on Biology and Medicine, Fall 1970, pp. 383-384. c. Cephalometric Study of Maxillary Growth Five Years After Alveolar R.M., Barnett, R., and Lewis, S.R., Plastic Reconstructive Surgery, December 1970, pp. 564-567. d. Mucoyst (Acetlycysteine) in the Treatment of Corneal Alkali Burns, Evans, R.M., Mc Crary, J.A., III, and Christensen, G., Annals of Ophthalmology, April 1972, pp. 320-322,324,328. e. Malignant Melanoma of the Choroid Associated With Spontaneous Expulsive Choroidal Hemorrhage, Perry H.D., Hsiek, C., and Evans, R.M., American Journal of Ophthalmology, October 1978, pp. 557-564.
g. Retinoblastoma, Evans, R.M., Bulletin of the Society of Military Ophthalmologists, October 1980, pp. 41-46. h. Anterior Encephalocoele, Evans, R.M., Rashid, E.R., and Bergstrom, T.J., Convention Reporter--American Academy of Ophthalmology, January 1981, p. 12. i. Linear Sebaceous Nevus Syndrome, Lambert, H.M., Sipperley, J.O., Shore, J.W., Dieckert, J.P., Evans, R.M., and Lowd, D.K., Ophthalmology, March 1987. j. A Vacation in Honduras, Evans, R.M., San Antonio Medicine, June 1997. k. Honduras Mission Trip and Hurricane Mitchell, Fox TV, Evans, R.M., San Antonio, Texas, November 1998.
SPECIAL POSTER PRESENTATIONS
1. American Academy of Ophthalmology, Annual Meeting 1977 2. American Academy of Ophthalmology, Annual Meeting 1978 3. American Academy of Ophthalmology, Annual Meeting 1979
2011
Ocular Safety of INS365 Ophthalmic Solution: A P2Y² Agonist In Healthy Subjects
A One-Week Comfort Study of BID-Dosed Brinzolamide 1%/Timolol 0.5% Ophthalmic Solution Fixed Combination Compared to BID-Dosed Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Multicenter, Paired-Eye Comparison, Dose-Escalation, Single Dose, 24-Month Study of Safety and Efficacy of Bimatoprost Preservative Free Intracameral Drug Delivery System (Bimatoprost PF IC DDS) in Patients with Open-Angle Glaucoma
An Investigator-Masked, Dose-Escalation Study to Determine the Safety, Toleralbility, Pharmacokinetics, and Efficacy of OPA-6566 Ophthalmic Solution in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Solution, 0.18% in Dry Eye Syndrome
A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 03%Comparer to TRAVATAN in Patients with Glaucoma or Ocular Hypertension
A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of Bimatoprost 0.03%/Timolol 0.5% Preservative-free Ophthalmic Solution Compared with GANFORT® (bimatoprost 0.03%/timolol 0.05% ophthalmic solution) Once Daily for12 Weeks in Patients with Glaucoma or Ocular Hypertension
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
A 2-Month, Double –Masked Study to Evaluate the Safety and IOP-Lowering Effects of AGN-210669 Ophthalmic Solution Compared with LUMIGAN® as Monotherapy, and as Adjunctive Therapy (AGN-210669 Plus LUMIGAN®), in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
A safety and Efficacy Comparison of Travoprost Ophthalmic Solution 0.00033% Administered 12 Times Daily to TRAVATAN 0.004% QD in Patients with Open-Angle Glaucoma or Ocular Hypertension
2010
A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of Bimatoprost 0.03% Preservative-free Ophthalmic Solution Compared with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) Once Daily for 12 Weeks in Patients with Glaucoma or Ocular Hypertension
A 2-Part Multicenter, Double-Masked, Randomized Study of the Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared to LUMIGAN® in Patients with Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 2, Double-Masked, Randomized, Active-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients with Elevated Intraocular Pressure
A Five Day Posology Study of Travoprost Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients with Open-Angle Glaucoma or Ocular Hypertension
2009
A 4-Week, Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of AGN-210669 0.05%, 0.075% and 0.1% Ophthalmic Solution Compared with LUMIGAN® in Patients with Ocular Hypertension or Primary Open-Angle Glaucoma
Safety and IOP-Lowering Efficacy of Brinzolamide/Brimonidine Fixed Combination Ophthalmic Suspension in Patients with Open-Angle Glaucoma and /or Ocular Hypertension
A phase 2, double-masked, randomized, placebo-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in patients with elevated intraocular pressure.
A multi-center, double-masked study of the safety and efficacy of Tarvoprost APS compared to TRAVATAN® in patients with open-angle glaucoma or ocular hypertension
A Phase I/II Prospective, Randomized, Double Masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 In Subjects with Dry Eye Disease
An Evaluation of the Ocular Surface Health in Subjects Using Travatan Z® Ophthalmic Solution Versus Xalatan® Ophthalmic Solution
A 2-Week, Multicenter, Double-Masked, Randomized, Parallel Study of the safety and efficacy of AGN 210669 ophthalmic solution compared with Lumigan® and AGN 210669 Vehicle in Subjects with Ocular Hypertension or Primary Open Angle Glaucoma
A Four-Week Study of the Safety and IOP-lowering Efficacy of AL-39256 Compared to Xalatan ® and Vehicle in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Phase I/II Prospective, Randomized, Double-Masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 in Subjects with Dry Eye Disease
2008
An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus Xalatan® Ophthalmic Solution
A Four-Week Study of the Safety and IOP-Lowering Efficacy of AL-39256 Compared to Xalatan® and Vehicle in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Multi-Dose Study of the Safety and IOP-Lowering Efficacy with Anecortave Acetate in Patients with Open-Angle Glaucoma
A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004% /Timolol 0.5% BAC-Free Compared to Travoprost 0.004%/Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension
Comparison of Safety and IOP-Lowering Efficacy of Three Alternative Travoprost Formulations to Vehicle and TRAVATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Randomized, Double-Masked, Placebo-and-Active-controlled, Parallel-group, Multi-center, Dose response Trial of DE-104 Ophthalmic Solution in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
Comparison of Safety and Efficacy of AL-37807 Ophthalmic Suspension vs. Timolol® Gel Forming Solution and Vehicle, All Dosed Concomitantly with XALATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension
2007
An Eighteen Week, Multi-Center, Investigator-Masked, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Bimatoprost 0.03% (LUMIGAN®) Ophthalmic Solution Once-Daily (QD) Compared with Lantanoprost 0.005% (Xalatan®) Ophthalmic Solution QD Following Six Weeks of Treatment with Xalatan® QD in Subjects with Glaucoma or Ocular Hypertension
A Multi Center, Double Masked, Randomized Parallel Group Study Evaluating the Safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks of Anterior Segment Inflammation, Pain, and Inhibition of Surgically Induced Miosis Following Cataract Extraction wit Posterior Chamber Intraocular Lens (IOL) Implantation
Safety and IOP-Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions dosed BID compared to TRAVATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension
IOP-lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Phase II, First-In-Human Dose-escalation, Double-Masked, Randomized, Vehicle-controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure
A Phase II, Prospective, Randomized, Observer-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 (0.002% and 0.006% Rivoglitazone HCL) Compared to Palcebo for the Treatment of Dry Eye Disease
2006
A 12-Week, randomized, double-masked, parallel group comparison of Xalacom™ given in the evening, Xalatan® given in the evening, and timolol given in the morning in subjects with open angle glaucoma or ocular hypertension in the United States
Safety and Efficacy of 1% AL-37807 Ophthalmic Suspension in Patients with Open-Angle Glaucoma or Ocular Hypertension
A One-Week Comfort Study of BID Dosed Brinzolamide 1.0%/Timolol 0.5% Ophthalmic Suspension Compared to BID Dosed COSOPT® in Patients with Open-Angle Glaucoma or Ocular Hypertension
2005
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT® in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Multicenter, Double-Masked, Randomized, Parallel, Active-Controlled Three Month Study (Plus 9-Month, Masked Extension) Of The Safety and Efficacy Of Bimatoprost Ophthalmic Solution 0.01% And Bimatoprost Ophthalmic Solution 0.0125% Once-Daily Compared to Lumigan® (Bimatoprost Ophthalmic Solution) 0.03% Once-Daily In Patients With Glaucoma or Ocular Hypertension
A Randomized, Double-Masked, Parallel-Group Dose-Response Trial Comparing the Safety and Efficacy of DE-092 Ophthalmic Solution with 0.5% Timolol Maleate in Subjects with Open-Angle Glaucoma or Ocular Hypertension
A Study to Assess the Safety and Efficacy of AL-37807 Ophthalmic Suspension Compared to Xalatan®, Timolol, and Vehicle in Patients with Open-Angle Glaucoma or Ocular Hypertension
A 5-DAY, MULTICENTER, DOUBLE-MASKED, RANDOMIZED, PAIRED-EYE COMPARISON, ACTIVE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF BIMATOPROST 0.01%, BIMATPROST 0.015% WITH EDTA, BIMATOPROST 0.015%, AND BIMATOPROST 0.02% ONCE-DAILY COMPARED WITH LUMIGAN® ( BIMATOPROST 0.03%) OPHTHALMIC SOLUTION ONCE-DAILY IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
A Randomized, Double-Masked, Parallel-group Dose-Response Trial Comparing the Safety and Efficacy of DE-092 Ophthalmic Solution with 005% Timolol Maleate in Subjects with Open-Angle Glaucoma or Ocular Hypertension
A 3 year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema
2004
A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration – Sub-Investigator
A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment–Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) Compared to Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration – Sub-Investigator
A Six Month Phase 3, Multi-center, Masked, Randomized, Sham-controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion -- Sub-Investigator
A Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Xalatan® and Timolol 0.5% Dosed Concomitantly in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Multicenter, Double-Masked, Study of the Safety and Efficacy of TRAVATAN BAC-free Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension
A study to evaluate the clinical and microbial efficacy and safety of 1.0% Azasite™ compared to vehicle in the treatment of Bacterial Conjunctivitis
A Randomized, Double-Masked, Parallel-Group, Multicenter, 12-Month Trial Comparing the Efficacy and Safety of Tafluprost 0.0015% with Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension
A Multi-Center, Double-Masked, Randomized, Parallel, Three-Week Study Of The Safety And Efficacy Of Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic Solution Once Daily, Bimatoprost 0.03% Once Daily And Timolol 0.5% Twice Daily Ophthalmic Solutions Dosed Concurrently, And Bimatoprost 0.03% Once Daily Ophthalmic Solution In Treatment-Naïve Patients With Glaucoma Or Ocular Hypertension
2003
A multi-center, double-masked, randomized, parallel, three month study (plus 9-month, masked extension) of the safety and efficacy of 0.1% Brimonidine Purite™ ophthalmic solution dosed three-times daily compared with 0.2% Brimonidine Tartrate Ophthalmic Solution dosed three-times daily in patients with glaucoma or ocular hypertension
A Three Month, Randomized, Double Masked, Parallel Group, Primary Therapy Study, with a Planned Nine-Month Extension, of the Safety and IOP Lowering Efficacy of Brimonidine Tartrate Ophthalmic Sloution, 0.15% Compared to ALPHAGAN ®P, 0.15% in Patients with Open Angle Glaucoma or Ocular Hypertension
A Multicenter, Double-Masked, Randomized, Parallel, Vehicle-Controlled, Two Week Study of the Safety, Tolerability, and Efficacy of Once-Daily Bimatoprost 0.03% Ophthalmic Solution Administered in Microdrop Volumes of 5μL, 10μL, 15μL and 20μL Compared with the Marketed Volume (30μL) in Patients with Glaucoma or Glaucoma Suspects.
A Multicenter, Double-Masked, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of BID-Dosed AL-34662 Ophthalmic Solution in Patients with Open Angle Glaucoma or Ocular Hypertension.
A Multicenter, Double-Masked, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Once-Daily AL12182 Ophthalmic Solution in Patients with Open Angle Glaucoma or Ocular Hypertension.
2002
A Three-Month, MultiCenter, Double-Masked, Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to TRAVATAN® and Timolol 0.5% in subjects with Open-Angle Glaucoma or Ocular Hypertension.
A Three-Month, MultiCenter, Double-Masked, Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to TRAVATAN® and Timolol 0.5% Dosed Concomitantly in Subjects with Open-Angle Glaucoma or Ocular Hypertension.
2001
A One-Month, Multicenter, Double-Masked, Randomized, Parallel-Group Study to evaluate the safety and acceptability of ReliefPlus® eyedrops compared to Visine® original eyedrops in normal volunteers
A Multicenter, double-masked, randomized, 3-arm parallel study, for 3 months (with a 9-month, masked extension) of the safety and efficacy of Bimatoprost 0.03%/Timolol 0.5% combination ophthalmic solution once daily compared with Timolol 0.5% monotherapy twice daily and Bimatoprost 0.03% monotherapy once daily in patients with glaucoma or ocular hypertension
A Double-Masked, Randomized, Twelve-Week Study to Assess the IOP-Lowering Efficacy and Safety of TID-Dosed Anecortave Acetate 2% Ophthalmic Suspension vs. TID-Dosed Brinzolamide 1% Ophthalmic Suspension in Patients with Primary Open-Angle Glaucoma
A Multicenter, Investigator-Masked, Randomized, Parallel Study of the Efficacy and Safety of AGN 192024 0.03% QD Administered Adjunctively with Brimonidine 0.2% BID Compared with Latanoprost 0.005% QD Administered Adjunctively with Timolol 0.5% BID in Patients with Glaucoma or Ocular Hypertension
A Parallel, Randomized, Observer-Masked, Multicenter Study Comparing the Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Meleate Combination Ophthalmic Solution to the Concomitant Administration of 0.2% Brimonidine Tartrate Ophthalmic solution and 0.5% Timolol Meleate Ophthalmic Solution in Patients with Elevated Intraocular Pressure
A Randomized, Double-Masked, Parallel-Group, Multi-Center Dose-Response Trail of AFP-168 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Second Year of Treatment in a One Year Multi-Center, Double-Masked, Placebo-Controlled, Parallel, Safety and Efficacy Study of 2% Pirenzepine Ophthalmic Gel in Children with Myopia
2000
A Six-Week, Double-Masked, Parallel Group Study to Compare the IOP-Lowering Efficacy and Safety of BID-Dosed Levobetaxolol 0.5% Ophthalmic Suspension (BETAXON™) vs. BID-Dosed Brimonidine Tartrate 0.2% Ophthalmic Solution (ALPHAGAN®) in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Double-Masked, Randomized Study to Compare the Signs and Symptoms of Ocular Allergy to BETAXON™ vs. ALPHAGAN® in Patients With Demonstrated Ocular Allergy to ALPHAGAN®
A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution Twice-Daily Compared with 0.5% Timolol Twice-Daily of Alphagan® Three-Times-Daily for Three Months (Plus 9-Month, Masked Extension) in Patients with Glaucoma or Ocular Hypertension
A One Year Multi-Center, Double-Masked, Placebo-Controlled, Parallel, Safety and Efficacy Study of 2% Pirenzepine Ophthalmic Gel in Children with Myopia
A Multi-Center, Investigator-Masked, Randomized, Two-Period Cross-Over Study to Evaluate the Safety and Acceptability of COMPLETE® ComfortPLUS™ in a Modified Regimen vs. ReNu MultiPlus™ Among Monthly Replacement Hydrogel Lens Wearers
A 3-Month, Multicenter, Double-Masked, Randomized, Parallel Comparison of the Safety and Efficacy of 0.15% Brimonidine-Purite™ Ophthalmic Solution BID vs. Alphagan® BID in Patients with Glaucoma or Ocular Hypertension Whose Intraocular Pressure is Controlled on Alphagan® BID Monotherapy
A Parallel, Randomized, Observer-Masked, Multicenter Study Comparing the Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Ophthalmic Solution to the Concomitant Administration of 0.2% Brimonidine Tartrate Ophthalmic Solution and 0.5% Timolol Maleate Ophthalmic Solution in Patients with Ocular Hypertension or Primary Open-Angle Glaucoma
A 3-Month Clinical Efficacy and Safety of a NO RUB Multi-Purpose Disinfecting Solution with All Lens Replacement Schedules
A Three-Month Comparison of the Safety, Efficacy, and Clinical Success of Brimonidine with Latanoprost vs Latanoprost with Timolol
1999
A 28-Day Study to clinically evaluate the presence of the Landec Punctal Occluder and the patency of the lacimal duct after one week daily qd dosing with DURATEARS NATURALE® in dry eye patients.
A Multicenter, Double-Masked, Randomized, Parallel, Three-month Study (with an extension to one year) of the Safety, Efficacy, and Acceptability of 0.15% and 0.2% Brimonidine-Purite ä Compared with 0.2% Brimonidine Administered Three-Times-Daily in subjects with Glaucoma or Ocular Hypertension
A Multicenter, Double-Masked, Randomized, Parallel, Three-Month Study (with treatment Extended to One Year) of the Safety and Efficacy of AGN-192024 0.03% Ophthalmic Solution, Administered Once- Daily or Twice-Daily Compared with Timolol 0.5% Ophthalmic Solution Administered Twice-Daily, in Subjects with Glaucoma or Ocular Hypertension
A Four-Week, Double-Masked, Parallel-Group, Viability Study to Assess the IOP-Lowering Efficacy and Safety of BID-Dosed AL-6598 0.012%/ Brimonudine 0.2% Combination vs. QD-Dosed Latanoprost 0.005% vs. BID-Dosed Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension
Genetic Testing For TIGR MT-1 And TIGR MT-11 Mutations In First Degree Offspring or Siblings of Primary Open-Angle Glaucoma Patients
A Double-Masked, Parallel Group, Viability Study to assess the IOP-Lowering Efficacy and Safety of BID-Dosed Brimonidine Tartrate 0.2% Ophthalmic Solution (ALPHAGAN ä ) Plus BID Dosed AL-6221 0.0015% Ophthalmic Solution vs. BID-Dosed AL-6221 0.0015% Ophthalmic Solution vs. Placebo in Patients with Ocular Hypertension or Open-Angle Glaucoma Who Have Had a Four-Week Run-In on QD-Dosed AL 6221 0.0015% Ophthalmic Solution
1998
A Three-Month Parallel, Observer-Masked, Multicenter Study Comparing the IOP-Lowering Effect of 0.005% Latanoprost QD to the 2%Dorzolamide/0.5% Timolol Combination BID in Patients With Elevated Intraocular Pressure
A Study To Determine if 0.06% or 0.1% ISV-205 is able to block an IOP Response When Dosed Concomitantly with Pred Forte â in Potential High Risk Steroid Responders for Six Weeks
A Six-Month, Multicenter, Triple-Masked, Placebo-Controlled Adjunctive Therapy Study of the Safety and Efficacy of AL-6221 0.0015% and AL-6221 0.004% Ophthalmic Solution Maintained on TIMOPTIC 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension
1997
A Four-Week, Multicenter, Triple-Masked, Placebo-Controlled, Dose-Response Study of the Safety & Efficacy of AL-6221 Ophthalmic Solution in the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
A Three-Month Multicenter, Triple-Masked, Parallel Study for Safety & Efficacy of Timolol Gel-Forming Solution 0.25%, dosed once daily, compared to TIMOPTIC 0.25% Ophthalmic Solution, dosed twice daily, in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension A Parallel, Randomized, Double-Masked, Active-Controlled, Multicenter Study Comparing the Tolerability and Efficacy of 2.0% Dorzolamide Ophthalmic Solution and Orally Administered Acetazolamide in Patients with Ocular Hypertension or Glaucoma
|
